Last reviewed · How we verify
Metamizol
At a glance
| Generic name | Metamizol |
|---|---|
| Also known as | Pyralgina, Pyralgin |
| Sponsor | Michał Borys |
| Target | Transient receptor potential cation channel subfamily A member 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis (PHASE3)
- Comparing the Safety and Effectiveness of Different Doses of Morphine Administered in Spinal Anethesia for Pain Relief After Hip Replacement Surgery (PHASE4)
- Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs (NA)
- Program to Avoid NSAIDs in Patients With Advanced Chronic Liver Disease (NA)
- Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. (NA)
- Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metamizol CI brief — competitive landscape report
- Metamizol updates RSS · CI watch RSS
- Michał Borys portfolio CI